Cripto: A novel target for antibody-based cancer immunotherapy

Cancer Research

Volumn 64, Issue 11, 2004, Pages 4018-4023

  Xing, Pei Xiang ^a   Hu, Xiu Feng ^a   Pietersz, Geoffrey A ^a   Hosick, Howard ^b   McKenzie, Ian F C ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CRIPTO PEPTIDE; EPIDERMAL GROWTH FACTOR; EPIRUBICIN; FLUOROURACIL; IMMUNOGLOBULIN M; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CRIPTO; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPEROXIDASE STAINING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2542588518     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3888     Document Type: Article

References (50)

1. Adamson ED, Minchiotti G, Salomon DS. Cripto: a tumor growth factor and more. J Cell Physiol 2002;190:267-78.
2. Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci 2001;6:D685-707.
3. Saloman DS, Bianco C, Ebert AD, et al. The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer 2000;7:199-226.
4. Shen MM, Schier AF. The EGF-CFC gene family in vertebrate development. Trends Genet 2000;16:303-9.
5. Minchiotti G, Parisi S, Liguori G, et al. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Mech Dev 2000;90:133-42.
6. Yan YT, Liu JJ, Luo Y, et al. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol 2002;22:4439-49.
7. Zhang J, Talbot WS, Schier AF. Positional cloning identifies zebrafish one-eyed pinhead as a permissive EGF-related ligand required during gastrulation. Cell 1998;92:241-51.
8. Bianco C, Adkins HB, Wechselberger C, et al. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial cells. Mol Cell Biol 2002;22:2586-97.
9. Minchiotti G, Parisi S, Liguori GL, D'Andrea D, Persico MG. Role of the EGF-CFC gene cripto in cell differentiation and embryo development. Gene 2002;287:33-7.
10. Ding J, Yang L, Yan YT, et al. Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo. Nature 1998;395:702-7.
11. Herrington EE, Ram TG, Salomon DS, et al. Expression of epidermal growth factor-related proteins in the aged adult mouse mammary gland and their relationship to tumorigenesis. J Cell Physiol 1997;170:47-56.
12. De Luca A, Casamassimi A, Selvam MP, et al. EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. Int J Cancer 1999;80:589-94.
13. Salomon DS, Bianco C, De Santis M. Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bioessays 1999;21:61-70.
14. Kenney NJ, Smith GH, Maroulakou IG, et al. Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice. Mol Carcinog 1996;15:44-56.
15. Niemeyer CC, Spencer-Dene B, Wu JX, Adamson ED. Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice. Int J Cancer 1999;81:588-91.
16. Ebert AD, Wechselberger C, Nees M, et al. Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells. Exp Cell Res 2000;257:223-9.
17. Wechselberger C, Ebert AD, Bianco C, et al. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res 2001;266:95-105.
18. Ciardiello F, Kim N, Saeki T, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA 1991;88:7792-6.
19. Qi CF, Liscia DS, Normanno N, et al. Expression of transforming growth factor α, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer 1994;69:903-10.
20. Friess H, Yamanaka Y, Buchler M, Kobrin MS, Tahara E, Korc M. Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis. Int J Cancer 1994;56:668-74.
21. Panico L, D'Antonio A, Salvatore G, et al. Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 1996;65:51-6.
22. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4:241-9.
23. D'Antonio A, Losito S, Pignata S, et al. Transforming growth factor α, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol 2002;21:941-8.
24. Bianco C, Strizzi L, Rehman A, et al. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 2003;63:1192-7.
25. Bianco C, Kannan S, De Santis M, et al. Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. J Biol Chem 1999;274:8624-9.
26. Kannan S, De Santis M, Lohmeyer M, et al. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem 1997;272:3330-5.
27. Ebert AD, Wechselberger C, Frank S, et al. Cripto-1 induces phosphatidylinositol 3′-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3β in human cervical carcinoma cells. Cancer Res 1999;59:4502-5.
28. Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci USA 2003;100:5193-8.
29. Chen YG, Lui HM, Lin SL, Lee JM, Ying SY. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood) 2002;227:75-87.
30. Matzuk MM, Kumar TR, Shou W, et al. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog Horm Res 1996;51:123-54; discussion 155-7.
31. Adkins HB, Bianco C, Schiffer SG, et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Investig 2003;112:575-87.
32. Xing PX, Apostolopoulos V, Pietersz G, McKenzie IF. Anti-mucin monoclonal antibodies. Front Biosci 2001;6:D1284-95.
33. Xing PX, Lees C, Lodding J, et al. Mouse mucin 1 (MUC1) defined by monoclonal antibodies. Int J Cancer 1998;76:875-83.
34. Hu XF, Slater A, Kantharidis P, et al. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 1999;93:4086-95.
35. Hu XF, Martin TJ, Bell DR, de Luise M, Zalcberg JR. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 1990;50:2953-7.
36. Hu XF, Veroni M, De Luise M, et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993;55:873-6.
37. Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575-80.
38. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992;359:552-4.
39. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002;8:S19-26.
40. De Luca A, Selvam MP, Sandomenico C, et al. Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. Int J Cancer 1997;73:277-82.
41. Normanno N, Tortora G, De Luca A, et al. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucteotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep 1999;6:1105-9.
42. Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-61.
43. Fukuyama R, Shimizu N. Expression of epidermal growth factor (EGF) and the EGF receptor in human tissues. J Exp Zool 1991;258:336-43.
44. Jnngbluth AA, Stockert E, Huang HJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 2003;100:639-44.
45. Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/ SAPK signaling cascade. Blood 1999;94:1382-92.
46. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002;99:1314-9.
47. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
48. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002;107:176-82.
49. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
50. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.